Christopher J. Sayed

1 month ago | healthcentral.com | James Roland |Christopher J. Sayed

Even though the inflammatory skin condition hidradenitis suppurativa (HS) affects up to 1.5 million people in the United States, there has long been a scarcity of resources to help people living with the condition, their families, and even healthcare professionals who have little experience diagnosing and treating HS.

Jan 22, 2025 | ajmc.com | Maggie L. Shaw |Christopher J. Sayed

Bringing our discussion with Christopher Sayed, MD, dermatologist and professor at the University of North Carolina at Chapel Hill Department of Dermatology, to a close, he discusses the initial appearance of hidradenitis suppurativa (HS), explaining the ages at which the chronic, painful skin disease typically manifests. He also looks to the future of patient treatment, following the November 2024 approval bimekizumab (Bimzelx; UCB Pharma) in patients who have moderate to severe HS.